(Q53339839)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23434730%20AND%20SRC:MED&resulttype=core&format=json

24 February 2020

title

A G polymorphism in the CRBN gene acts as a biomarker of response to treatment with lenalidomide in low/int-1 risk MDS without del(5q) (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23434730%20AND%20SRC:MED&resulttype=core&format=json

24 February 2020

1 reference

13

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23434730%20AND%20SRC:MED&resulttype=core&format=json

24 February 2020

Valeria Santini

8

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23434730%20AND%20SRC:MED&resulttype=core&format=json

24 February 2020

Sophie Park

9

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23434730%20AND%20SRC:MED&resulttype=core&format=json

24 February 2020

Olivier Kosmider

14

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23434730%20AND%20SRC:MED&resulttype=core&format=json

24 February 2020

11

P Fenaux

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23434730%20AND%20SRC:MED&resulttype=core&format=json

24 February 2020

author name string

V Sardnal

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23434730%20AND%20SRC:MED&resulttype=core&format=json

24 February 2020

A Rouquette

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23434730%20AND%20SRC:MED&resulttype=core&format=json

24 February 2020

S Kaltenbach

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23434730%20AND%20SRC:MED&resulttype=core&format=json

24 February 2020

C Bally

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23434730%20AND%20SRC:MED&resulttype=core&format=json

24 February 2020

V Chesnais

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23434730%20AND%20SRC:MED&resulttype=core&format=json

24 February 2020

C Leschi

6

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23434730%20AND%20SRC:MED&resulttype=core&format=json

24 February 2020

L Ades

7

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23434730%20AND%20SRC:MED&resulttype=core&format=json

24 February 2020

A Toma

10

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23434730%20AND%20SRC:MED&resulttype=core&format=json

24 February 2020

F Dreyfus

12

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23434730%20AND%20SRC:MED&resulttype=core&format=json

24 February 2020

publication date

26 February 2013

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23434730%20AND%20SRC:MED&resulttype=core&format=json

24 February 2020

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23434730%20AND%20SRC:MED&resulttype=core&format=json

24 February 2020

volume

27

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23434730%20AND%20SRC:MED&resulttype=core&format=json

24 February 2020

issue

7

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23434730%20AND%20SRC:MED&resulttype=core&format=json

24 February 2020

page(s)

1610-1613

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23434730%20AND%20SRC:MED&resulttype=core&format=json

https://scigraph.springernature.com/pub.10.1038/leu.2013.59

24 February 2020

exact match

0 references

cites work

Identification of a primary target of thalidomide teratogenicity

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2013.59

Cereblon is a direct protein target for immunomodulatory and antiproliferative activities of lenalidomide and pomalidomide

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2013.59

Immunomodulatory drugs in multiple myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2013.59

Immunomodulating drugs in myelodysplastic syndromes

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2013.59

Lenalidomide in the myelodysplastic syndrome with chromosome 5q deletion

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2013.59

Phase 2 study of lenalidomide in transfusion-dependent, low-risk, and intermediate-1 risk myelodysplastic syndromes with karyotypes other than deletion 5q.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2013.59

Cereblon expression is required for the antimyeloma activity of lenalidomide and pomalidomide.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2013.59

High cereblon expression is associated with better survival in patients with newly diagnosed multiple myeloma treated with thalidomide maintenance.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2013.59

Thalidomide produces transfusion independence in long-standing refractory anemias of patients with myelodysplastic syndromes.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2013.59

A randomized phase 3 study of lenalidomide versus placebo in RBC transfusion-dependent patients with Low-/Intermediate-1-risk myelodysplastic syndromes with del5q.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2013.59

Combined treatment with lenalidomide and epoetin alfa in lower-risk patients with myelodysplastic syndrome.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2013.59

An erythroid differentiation signature predicts response to lenalidomide in myelodysplastic syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2013.59

Cytogenetic and molecular predictors of response in patients with myeloid malignancies without del[5q] treated with lenalidomide.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2013.59

Lenalidomide promotes p53 degradation by inhibiting MDM2 auto-ubiquitination in myelodysplastic syndrome with chromosome 5q deletion

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2013.59

21 January 2018

Identifiers

DOI

10.1038/LEU.2013.59

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23434730%20AND%20SRC:MED&resulttype=core&format=json

24 February 2020

1 reference